Rival Abbott launched its own OTC CGM, Lingo, weeks after Dexcom's Stelo debut. The company is counting on further international expansion to drive growth after it said it had improved access to ...

Despite the setbacks, DexCom has been actively working on several strategic initiatives to address its challenges and position itself for future growth: 1. Stelo CGM Launch: In August 2024 ...

Despite the setbacks, DexCom has been actively working on several strategic initiatives to address its challenges and position itself for future growth: 1. Stelo CGM Launch: In August 2024, DexCom ...

DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...

Stelo is going to be a really interesting product ... And the one thing we do know is DexCom CGM has a very, very high utilization. If you look across the board in utilization, for folks that ...

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

Its innovative CGM systems, like the G6 and the newer G7 ... G7 system and further development of offerings like the Dexcom Stelo, targeting non-insulin-using diabetes patients.